Pick Topic
Review Topic
List Experts
Examine Expert
Save Expert
  Site Guide ··   
Irritable Bowel Syndrome HELP
Based on 4,665 articles published since 2008
||||

These are the 4665 published articles about Irritable Bowel Syndrome that originated from Worldwide during 2008-2018.
 
+ Citations + Abstracts
Pages: 1 · 2 · 3 · 4 · 5 · 6 · 7 · 8 · 9 · 10 · 11 · 12 · 13 · 14 · 15 · 16 · 17 · 18 · 19 · 20
1 Guideline Consensus Statement of Definitions for Anorectal Physiology Testing and Pelvic Floor Terminology (Revised). 2018

Bordeianou, Liliana G / Carmichael, Joseph C / Paquette, Ian M / Wexner, Steven / Hull, Tracy L / Bernstein, Mitchell / Keller, Deborah S / Zutshi, Massarat / Varma, Madhulika G / Gurland, Brooke H / Steele, Scott R. ·Prepared on behalf of the Pelvic Floor Disorders Committee and the Clinical Practice Guidelines Committee of The American Society of Colon and Rectal Surgeons. ·Dis Colon Rectum · Pubmed #29521821.

ABSTRACT: -- No abstract --

2 Guideline The current treatment landscape of irritable bowel syndrome in adults in Hong Kong: consensus statements. 2017

Wu, J Cy / Chan, A Oo / Chan, Y W / Cheung, G Cl / Cheung, T K / Kwan, A Cp / Leung, V Ks / Mak, A Dp / Sze, W C / Wong, R. ·Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Shatin, Hong Kong. · Department of Gastroenterology and Hepatology, Hong Kong Sanatorium & Hospital, Happy Valley, Hong Kong. · Hong Kong Institute of Integrative Medicine, The Chinese University of Hong Kong, Shatin, Hong Kong. · Hong Kong Nutrition Association, Hong Kong. · Private specialist in Gastroenterology and Hepatology, Hong Kong. · Department of Gastroenterology and Hepatology, Hong Kong Baptist Hospital, Kowloon Tong, Hong Kong. · Department of Psychiatry, The Chinese University of Hong Kong, Shatin, Hong Kong. ·Hong Kong Med J · Pubmed #29226832.

ABSTRACT: OBJECTIVE: The estimated prevalence of irritable bowel syndrome in Hong Kong is 6.6%. With the increasing availability of pharmacological and non-pharmacological treatments, the Hong Kong Advisory Council on Irritable Bowel Syndrome has developed a set of consensus statements intended to serve as local recommendations for clinicians about diagnosis and management of irritable bowel syndrome. PARTICIPANTS: A multidisciplinary group of clinicians constituting the Hong Kong Advisory Council on Irritable Bowel Syndrome-seven gastroenterologists, one clinical psychologist, one psychiatrist, and one nutritionist-convened on 20 April 2017 in Hong Kong. EVIDENCE: Published primary research articles, meta-analyses, and guidelines and consensus statements issued by different regional and international societies on the diagnosis and management of irritable bowel syndrome were reviewed. CONSENSUS PROCESS: An outline of consensus statements was drafted prior to the meeting. All consensus statements were finalised by the participants during the meeting, with 100% consensus. CONCLUSIONS: Twenty-four consensus statements were generated at the meeting. The statements were divided into four parts covering: (1) patient assessment; (2) patient's psychological distress; (3) dietary and alternative approaches to managing irritable bowel syndrome; and (4) evidence to support pharmacological management of irritable bowel syndrome. It is recommended that primary care physicians assume the role of principal care provider for patients with irritable bowel syndrome. The current statements are intended to guide primary care physicians in diagnosing and managing patients with irritable bowel syndrome in Hong Kong.

3 Guideline [Irritable bowel syndrome with constipation and functional constipation in adults: Treatment (Part 2 of 2)]. 2017

Mearin, F / Ciriza, C / Mínguez, M / Rey, E / Mascort, J J / Peña, E / Cañones, P / Júdez, J / Anonymous981087. ·Coordinación de la GPC, Comité Roma de Trastornos Funcionales Intestinales, Asociación Española de Gastroenterología (AEG), Centro Médico Teknon, Barcelona, España. · Grupo de Trastornos Funcionales, Sociedad Española de Patología Digestiva (SEPD), Hospital Universitario Doce de Octubre, Madrid, España. · AEG y SEPD, Hospital Clínico Universitario, Universitat de Valencia, Valencia, España. · SEPD, Hospital Clínico Universitario San Carlos, Madrid, España. · Secretaría Científica, Sociedad Española de Medicina de Familia y Comunitaria (semFYC), España. Electronic address: jmascort@semfyc.es. · Coordinación de Digestivo, Sociedad Española de Médicos de Atención Primaria (SEMERGEN), España. · Coordinación de Digestivo, Sociedad Española de Médicos Generales y de Familia (SEMG), España. · Departamento de Gestión del Conocimiento, SEPD, España. ·Aten Primaria · Pubmed #28238460.

ABSTRACT: In this Clinical practice guide we examine the diagnostic and therapeutic management of adult patients with constipation and abdominal discomfort, at the confluence of the spectrum of irritable bowel syndrome and functional constipation. Both fall within the framework of functional intestinal disorders and have major personal, health and social impact, altering the quality of life of the patients affected. The former is a subtype of irritable bowel syndrome in which constipation and altered bowel habit predominate, often along with recurring abdominal pain, bloating and abdominal distension. Constipation is characterised by infrequent or hard-to-pass bowel movements, often accompanied by straining during defecation or the sensation of incomplete evacuation. There is no underlying organic cause in the majority of cases; it being considered a functional bowel disorder. There are many clinical and pathophysiological similarities between the two conditions, the constipation responds in a similar way to commonly used drugs, the fundamental difference being the presence or absence of pain, but not in an "all or nothing" way. The severity of these disorders depends not only on the intensity of the intestinal symptoms but also on other biopsychosocial factors: association of gastrointestinal and extraintestinal symptoms, degree of involvement, forms of perception and behaviour. Functional bowel disorders are diagnosed using the Rome criteria. This Clinical practice guide adapts to the Rome IV criteria published at the end of May 2016. The first part (96, 97, 98) examined the conceptual and pathophysiological aspects, alarm criteria, diagnostic test and referral criteria between Primary Care and Gastroenterology. This second part reviews all the available treatment alternatives (exercise, fluid ingestion, diet with soluble fibre-rich foods, fibre supplements, other dietary components, osmotic or stimulating laxatives, probiotics, antibiotics, spasmolytics, peppermint essence, prucalopride, linaclotide, lubiprostone, biofeedback, antdepressants, psychological treatment, acupuncture, enemas, sacral root neurostimulation and surgery), and practical recommendations are made for each.

4 Guideline [Clinical practice guidelines: Irritable bowel syndrome with constipation and functional constipation in adults: Concept, diagnosis, and healthcare continuity. (Part 1 of 2)]. 2017

Mearin, F / Ciriza, C / Mínguez, M / Rey, E / Mascort, J J / Peña, E / Cañones, P / Júdez, J / Anonymous1501058 / Anonymous1511058 / Anonymous1521058 / Anonymous1531058 / Anonymous1541058 / Anonymous1551058 / Anonymous1561058. ·Coordinación de la guía de práctica clínica (GPC), Comité Roma de Trastornos Funcionales Intestinales, Asociación Española de Gastroenterología (AEG), Centro Médico Teknon, Barcelona, España. · Grupo de Trastornos Funcionales, Sociedad Española de Patología Digestiva (SEPD), Hospital Universitario Doce de Octubre, Madrid, España. · AEG y SEPD, Hospital Clínico Universitario, Universitat de Valencia, Valencia, España. · SEPD Hospital Clínico Universitario San Carlos, Madrid, España. · Secretaría Científica, Sociedad Española de Medicina de Familia y Comunitaria (semFYC), España. Electronic address: jmascort@semfyc.es. · Coordinación de Digestivo, Sociedad Española de Médicos de Atención Primaria (SEMERGEN), España. · Coordinación de Digestivo, Sociedad Española de Médicos Generales y de Familia (SEMG), España. · Departamento de Gestión del Conocimiento, SEPD, España. ·Aten Primaria · Pubmed #28027792.

ABSTRACT: In this Clinical practice guide, an analysis is made of the diagnosis and treatment of adult patients with constipation and abdominal discomfort, under the spectrum of irritable bowel syndrome and functional constipation. These have an important personal, health and social impact, affecting the quality of life of these patients. In irritable bowel syndrome with a predominance of constipation, this is the predominant change in bowel movements, with recurrent abdominal pain, bloating and frequent abdominal distension. Constipation is characterised by infrequent or difficulty in bowel movements, associated with excessive straining during bowel movement or sensation of incomplete evacuation. There is often no underling cause, with an intestinal functional disorder being considered. They have many clinical and pathophysiological similarities, with a similar response of the constipation to common drugs. The fundamental difference is the presence or absence of pain, but not in a way evaluable way; "all or nothing". The severity depends on the intensity of bowel symptoms and other factors, a combination of gastrointestinal and extra-intestinal symptoms, level of involvement, forms of perception, and behaviour. The Rome criteria diagnose functional bowel disorders. This guide is adapted to the Rome criteria IV (May 2016) and in this first part an analysis is made of the alarm criteria, diagnostic tests, and the criteria for referral between Primary Care and Digestive Disease specialists. In the second part, a review will be made of the therapeutic alternatives available (exercise, diet, drug therapies, neurostimulation of sacral roots, or surgery), making practical recommendations for each one of them.

5 Guideline British Dietetic Association systematic review and evidence-based practice guidelines for the dietary management of irritable bowel syndrome in adults (2016 update). 2016

McKenzie, Y A / Bowyer, R K / Leach, H / Gulia, P / Horobin, J / O'Sullivan, N A / Pettitt, C / Reeves, L B / Seamark, L / Williams, M / Thompson, J / Lomer, M C E / Anonymous671263. ·Nuffield Health The Manor Hospital, Oxford, UK. yvonne@digestiblenutrition.co.uk. · Department of Nutrition and Dietetics, Great Western Hospitals NHS Foundation Trust, Swindon, UK. · Department of Nutrition and Dietetics, Southampton NHS Foundation Trust, Southampton, UK. · Dr Ashok Ayurveda Clinic, Birmingham, UK. · Department of Nutrition and Dietetics, North Middlesex University Hospital NHS Trust, London, UK. · Faculty of Life Sciences and Medicine, Diabetes and Nutritional Sciences Division, King's College London, London, UK. · Faculty of Medicine, Imperial College London, London, UK. · Allergy Services, Oxford University Hospitals NHS Foundation Trust, Oxford, UK. · Specialist Gastroenterology Community Dietetic Service, Somerset Partnership NHS Foundation Trust, Bridgwater, UK. · Calm Gut Clinic, Todmorden, UK. · Department of Nutrition and Dietetics, St Thomas' Hospital, Guy's and St Thomas' NHS Foundation Trust, London, UK. ·J Hum Nutr Diet · Pubmed #27272325.

ABSTRACT: BACKGROUND: The first British Dietetic Association (BDA) guidelines for the dietary management of irritable bowel syndrome (IBS) in adults were published in 2012. Subsequently, there has been a wealth of new research. The aim of this work was to systematically review the evidence for the role of diet in the management of IBS and to update the guidelines. METHODS: Twelve questions relating to diet and IBS were defined based on review of the previous guideline questions, current evidence and clinical practice. Chosen topics were on healthy eating and lifestyle (alcohol, caffeine, spicy food, elimination diets, fat and fluid intakes and dietary habits), milk and dairy, dietary fibre, fermentable carbohydrates, gluten, probiotics and elimination diets/food hypersensitivity. Data sources were CINAHL, Cochrane Register of Controlled Trials, Embase, Medline, Scopus and Web of Science up to October 2015. Studies were assessed independently in duplicate using risk of bias tools specific to each included study based on inclusion and exclusion criteria for each question. National Health and Medical Research Council grading evidence levels were used to develop evidence statements and recommendations, in accordance with Practice-based Evidence in Nutrition Global protocol used by the BDA. RESULTS: Eighty-six studies were critically appraised to generate 46 evidence statements, 15 clinical recommendations and four research recommendations. The IBS dietary algorithm was simplified to first-line (healthy eating, provided by any healthcare professional) and second-line [low FODMAP (fermentable oligosaccharides, disaccharides, monosaccharides and polyols) to be provided by dietitian] dietary advice. CONCLUSIONS: These guidelines provide updated comprehensive evidence-based details to achieve the successful dietary management of IBS in adults.

6 Guideline British Dietetic Association systematic review of systematic reviews and evidence-based practice guidelines for the use of probiotics in the management of irritable bowel syndrome in adults (2016 update). 2016

McKenzie, Y A / Thompson, J / Gulia, P / Lomer, M C E / Anonymous661263. ·Nuffield Health, The Manor Hospital, Oxford, UK. yvonne@digestiblenutrition.co.uk. · Calm Gut Clinic, Todmorden, Lancashire, UK. · Dr Ashok Ayurveda Clinic, Birmingham, UK. · Diabetes and Nutritional Sciences Division, King's College London, London, UK. · Department of Nutrition and Dietetics, Guy's and St Thomas' NHS Foundation Trust, London, UK. ·J Hum Nutr Diet · Pubmed #27265510.

ABSTRACT: BACKGROUND: Probiotics are often taken by individuals with irritable bowel syndrome (IBS). Which products are effective is unclear, despite an increasing research base. This project will systematically review which strain- and dose- specific probiotics can be recommended to adults with IBS to improve symptoms and quality of life (QoL). It is part of a broader systematic review to update British Dietetic Association guidelines for the dietary management of IBS in adults. METHODS: CINAHL, Cochrane, Embase, Medline, Scopus and Web of Science were searched for systematic reviews (SRs) of randomised controlled trial (RCT)s recruiting adults with IBS comparing probiotic intervention with placebo. AMSTAR, risk of bias and diet bias tools were used to appraise methodological quality. Symptom and QoL data were appraised to develop probiotic-specific evidence statements on clinically meaningful and marginal outcomes in various settings, graded clinical practice recommendations and practical considerations. RESULTS: Nine systematic reviews and 35 RCTs were included (3406 participants) using 29 dose-specific probiotic formulations. None of the RCTs were at low risk of bias. Twelve out of 29 probiotics (41%) showed no symptom or QoL benefits. Evidence indicated that no strain or dose specific probiotic was consistently effective to improve any IBS symptoms or QoL. Two general clinical practice recommendations were made. CONCLUSIONS: Symptom outcomes for dose-specific probiotics were heterogeneous. Specific probiotic recommendations for IBS management in adults were not possible at this time. More data from high-quality RCTs treating specific symptom profiles are needed to support probiotic therapy in the management of IBS.

7 Guideline Pharmacologic Management of Irritable Bowel Syndrome. 2015

Rao, Vijaya L / Cifu, Adam S / Yang, Leslie W / Anonymous6260853. ·Section of Gastroenterology, Hepatology, and Nutrition, University of Chicago Medical Center, Chicago, Illinois. · Section of General Internal Medicine, University of Chicago Medical Center, Chicago, Illinois. ·JAMA · Pubmed #26720029.

ABSTRACT: -- No abstract --

8 Guideline Evidence-based clinical practice guidelines for irritable bowel syndrome. 2015

Fukudo, Shin / Kaneko, Hiroshi / Akiho, Hirotada / Inamori, Masahiko / Endo, Yuka / Okumura, Toshikatsu / Kanazawa, Motoyori / Kamiya, Takeshi / Sato, Ken / Chiba, Toshimi / Furuta, Kenji / Yamato, Shigeru / Arakawa, Tetsuo / Fujiyama, Yoshihide / Azuma, Takeshi / Fujimoto, Kazuma / Mine, Tetsuya / Miura, Soichiro / Kinoshita, Yoshikazu / Sugano, Kentaro / Shimosegawa, Tooru. ·Guidelines Committee for creating and evaluating the "Evidence-based clinical practice guidelines for irritable bowel syndrome", the Japanese Society of Gastroenterology (JSGE), K-18 Building 8F, 8-9-13 Ginza, Chuo, Tokyo, 104-0061, Japan, sfukudo@med.tohoku.ac.jp. ·J Gastroenterol · Pubmed #25500976.

ABSTRACT: New strategies for the care of irritable bowel syndrome (IBS) are developing and several novel treatments have been globally produced. New methods of care should be customized geographically because each country has a specific medical system, life style, eating habit, gut microbiota, genes and so on. Several clinical guidelines for IBS have been proposed and the Japanese Society of Gastroenterology (JSGE) subsequently developed evidence-based clinical practice guidelines for IBS. Sixty-two clinical questions (CQs) comprising 1 definition, 6 epidemiology, 6 pathophysiology, 10 diagnosis, 30 treatment, 4 prognosis, and 5 complications were proposed and statements were made to answer to CQs. A diagnosis algorithm and a three-step treatment was provided for patients with chronic abdominal pain or abdominal discomfort and/or abnormal bowel movement. If more than one alarm symptom/sign, risk factor and/or routine examination is positive, colonoscopy is indicated. If all of them, or the subsequent colonoscopy, are/is negative, Rome III or compatible criteria is applied. After IBS diagnosis, step 1 therapy consisting of diet therapy, behavioral modification and gut-targeted pharmacotherapy is indicated for four weeks. Non-responders to step 1 therapy proceed to the second step that includes psychopharmacological agents and simple psychotherapy for four weeks. In the third step, for patients non-responsive to step 2 therapy, a combination of gut-targeted pharmacotherapy, psychopharmacological treatments and/or specific psychotherapy is/are indicated. Clinical guidelines and consensus for IBS treatment in Japan are well suited for Japanese IBS patients; as such, they may provide useful insight for IBS treatment in other countries around the world.

9 Guideline The use of mebeverine in irritable bowel syndrome. A Position paper of the Romanian Society of Neurogastroenterology based on evidence. 2014

Dumitrascu, Dan L / Chira, Alexandra / Bataga, Simona / Diculescu, Mircea / Drug, Vasile / Gheorghe, Cristian / Goldis, Adrian / Nedelcu, Laurentiu / Porr, Paul J / Sporea, Ioan / Anonymous1520816. ·2nd Medical Department, Iuliu Hatieganu University of Medicine and Pharmacy, Cluj-Napoca, Romania. ddumitrascu@umfcluj.ro. · 2nd Medical Department, Iuliu Hatieganu University of Medicine and Pharmacy, Cluj-Napoca, Romania. · University of Medicine and Pharmacy, Tg-Mures, Romania. · Center of Gastroenterology and Hepatology, Fundeni Clinical Institute, Bucharest, Romania. · Gr. T. Popa University of Medicine and Pharmacy, Institute of Gastroenterology and Hepatology, Iasi, Romania. · Department of Gastroenterology and Hepatology, University of Medicine and Pharmacy, Timisoara, Romania. · Department of Internal Medicine, Transilvania University, Brasov, Romania. · Lucian Blaga University, Sibiu, Romania. ·J Gastrointestin Liver Dis · Pubmed #25532003.

ABSTRACT: -- No abstract --

10 Guideline American Gastroenterological Association Institute Guideline on the pharmacological management of irritable bowel syndrome. 2014

Weinberg, David S / Smalley, Walter / Heidelbaugh, Joel J / Sultan, Shahnaz / Anonymous4540806. ·Fox Chase Cancer Center, Philadelphia, Pennsylvania. · VA Tennessee Valley Healthcare System, Vanderbilt University, Nashville, Tennessee. · University of Michigan Ann Arbor, Michigan. · Department of Veterans Affairs Medical Center, Gastroenterology Section, North Florida/South Georgia Veterans Health System, Division of Gastroenterology, Hepatology, and Nutrition, University of Florida, Gainesville, Florida; Minneapolis Veterans Affairs Health System, University of Minnesota, Minneapolis, Minnesota. ·Gastroenterology · Pubmed #25224526.

ABSTRACT: -- No abstract --

11 Guideline [Joint Statement of the German Society for Digestive and Metabolic Diseases (DGVS), the German Society for Neurogastroenterology and motility (DGNM) and the German Society for Internal Medicine (DGIM) for linaclotide-benefit assessment of the Institute for Quality and Efficiency in Health Care (IQWiG) in accordance with § 35a SGB V (dossier evaluation)]. 2013

Andresen, V / Layer, P / Anonymous3840776 / Anonymous3850776 / Anonymous3860776. · ·Z Gastroenterol · Pubmed #24266047.

ABSTRACT: -- No abstract --

12 Guideline Intestinal microbiota in functional bowel disorders: a Rome foundation report. 2013

Simrén, Magnus / Barbara, Giovanni / Flint, Harry J / Spiegel, Brennan M R / Spiller, Robin C / Vanner, Stephen / Verdu, Elena F / Whorwell, Peter J / Zoetendal, Erwin G / Anonymous5510729. ·Department of Internal Medicine, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg S-41345, Sweden. magnus.simren@medicine.gu.se ·Gut · Pubmed #22730468.

ABSTRACT: It is increasingly perceived that gut host-microbial interactions are important elements in the pathogenesis of functional gastrointestinal disorders (FGID). The most convincing evidence to date is the finding that functional dyspepsia and irritable bowel syndrome (IBS) may develop in predisposed individuals following a bout of infectious gastroenteritis. There has been a great deal of interest in the potential clinical and therapeutic implications of small intestinal bacterial overgrowth in IBS. However, this theory has generated much debate because the evidence is largely based on breath tests which have not been validated. The introduction of culture-independent molecular techniques provides a major advancement in our understanding of the microbial community in FGID. Results from 16S rRNA-based microbiota profiling approaches demonstrate both quantitative and qualitative changes of mucosal and faecal gut microbiota, particularly in IBS. Investigators are also starting to measure host-microbial interactions in IBS. The current working hypothesis is that abnormal microbiota activate mucosal innate immune responses which increase epithelial permeability, activate nociceptive sensory pathways and dysregulate the enteric nervous system. While we await important insights in this field, the microbiota is already a therapeutic target. Existing controlled trials of dietary manipulation, prebiotics, probiotics, synbiotics and non-absorbable antibiotics are promising, although most are limited by suboptimal design and small sample size. In this article, the authors provide a critical review of current hypotheses regarding the pathogenetic involvement of microbiota in FGID and evaluate the results of microbiota-directed interventions. The authors also provide clinical guidance on modulation of gut microbiota in IBS.

13 Guideline British Dietetic Association evidence-based guidelines for the dietary management of irritable bowel syndrome in adults. 2012

McKenzie, Y A / Alder, A / Anderson, W / Wills, A / Goddard, L / Gulia, P / Jankovich, E / Mutch, P / Reeves, L B / Singer, A / Lomer, M C E / Anonymous990723. ·Nuffield Health The Manor Hospital, Oxford, UK Department of Nutrition and Dietetics, Royal Sussex County Hospital, Brighton, UK. ·J Hum Nutr Diet · Pubmed #22489905.

ABSTRACT: BACKGROUND:  Irritable bowel syndrome (IBS) is a chronic debilitating functional gastrointestinal disorder. Diet and lifestyle changes are important management strategies. The aim of these guidelines is to systematically review key aspects of the dietary management of IBS, with the aim of providing evidence-based guidelines for use by registered dietitians. METHODS: Questions relating to diet and IBS symptom management were developed by a guideline development group. These included the role of milk and lactose, nonstarch polysaccharides (NSP), fermentable carbohydrates in abdominal bloating, probiotics and empirical or elimination diets. A comprehensive literature search was conducted and relevant studies from January 1985 to November 2009 were identified using the electronic database search engines: Cinahl, Cochrane Library, Embase, Medline, Scopus and Web of Science. Evidence statements, recommendations, good practice points and research recommendations were developed. RESULTS: Thirty studies were critically appraised. A dietetic care pathway was produced following a logical sequence of treatment and formed the basis of these guidelines. Three lines of dietary management were identified. first line: Clinical and dietary assessment, healthy eating and lifestyle management with some general advice on lactose and NSP. Second line: Advanced dietary interventions to improve symptoms based on NSP, fermentable carbohydrates and probiotics. Third line: Elimination and empirical diets. Research recommendations were also identified relating to the need for adequately powered and well designed randomised controlled trials. CONCLUSIONS: These guidelines provide evidence-based details of how to achieve the successful dietary management of IBS.

14 Guideline [IBD ahead 2010--Answering important questions in Crohn's disease treatment]. 2011

Schmidt, C / Dignass, A / Hartmann, F / Hüppe, D / Kruis, W / Layer, P / Lüers, A / Stallmach, A / Teich, N / Sturm, A / Anonymous6220703. ·Universitätklinikum Jena, Klinik für Innere Medizin II, Abteilung für Gastroenterologie, Hepatologie und Infektiologie. ·Z Gastroenterol · Pubmed #21866492.

ABSTRACT: The treatment of patients with inflammatory bowel disease has become more complex in recent years through the introduction of various immunosuppressive agents as well as the approval of monoclonal antibodies against TNF-α and patients receiving such treatment must be carefully monitored. National and international guidelines define a diagnostic and therapeutic context for the practitioner, but can only partially respond to specific questions on the procedure for individual patients. Within the framework of a project initiated by Abbott entitled "IBD ahead" 38 German IBD experts have elaborated concrete proposals for dealing with corticosteroids, immunosuppressants and TNF-α antibodies on the basis of the published literature and their own personal experience in order to close the gap between these guidelines and daily clinical practice. Statements were developed on the choice of correct timing of initiation, dose and duration of the individual substances and on how to proceed with patients exhibiting treatment failure. Moreover, recommendations are also made on drug combination strategies, safety monitoring and the risks regarding the development of infectious complications and malignancies. These recommendations are illustrated by case studies from everyday practice in participating centres.

15 Guideline [Guidelines for the treatment of irritable bowel syndrome]. 2011

Kwon, Joong Goo / Park, Kyung Sik / Park, Jung Ho / Park, Jae Myung / Park, Cheol Hee / Lee, Kwang Jae / Park, Hyo Jin / Rhee, Jong Chul / Anonymous4200687. ·Department of Internal Medicine, Catholic University of Daegu School of Medicine, Korea. ·Korean J Gastroenterol · Pubmed #21350320.

ABSTRACT: Traditional symptom-based therapies of irritable bowel syndrome (IBS) are directed at the relief of individual IBS symptoms, but they are often of limited efficacy in addressing the entire symptom complex. Combinations of drugs to target bothersome symptoms are suggested as the first-line pharmacologic treatment. Increasing knowledge of the pathophysiology and molecular mechanisms of IBS has resulted in the development of several new therapeutic approaches. Thirteen consensus statements for the treatment of IBS were developed using the modified Delphi approach. Exclusion diets have modest efficacy in improving symptoms in some IBS patients. Symptom-based therapies with dietary fiber, bulking agents, laxatives, antispasmodics and laxatives are effective in the improvement of some individual symptoms, e.g. dietary fiber and bulking agents for constipation, laxatives for constipation, antispasmodics for abdominal pain and discomfort, antidiarrheals for diarrhea. 5HT3 receptor antagonists and 5HT((4)) receptor agonists are effective in the relief of global IBS symptoms and individual symptoms such as abdominal pain and abnormal bowel habits. A short term course of nonabsorbable antibiotics may improve global IBS symptoms, particularly in patients with diarrhea- predominant IBS. Some probiotics appear to have the potential benefit in improving global IBS symptoms. Selective C-2 chloride channel activator is more effective than placebo at relieving global IBS symptoms in patients with constipation-predominant IBS. Both tricyclic antidepressants and selective serotonin reuptake inhibitors are equally effective in relieving global IBS symptoms, and have some benefits in treating abdominal pain. Certain types of psychologic therapy may be effective in improving global symptoms in some IBS patients. Further studies are strongly needed to develop better treatment strategies for Korean patients with IBS.

16 Guideline [Irritable bowel syndrome: German consensus guidelines on definition, pathophysiology and management]. 2011

Layer, P / Andresen, V / Pehl, C / Allescher, H / Bischoff, S C / Classen, M / Enck, P / Frieling, T / Haag, S / Holtmann, G / Karaus, M / Kathemann, S / Keller, J / Kuhlbusch-Zicklam, R / Kruis, W / Langhorst, J / Matthes, H / Mönnikes, H / Müller-Lissner, S / Musial, F / Otto, B / Rosenberger, C / Schemann, M / van der Voort, I / Dathe, K / Preiss, J C / Anonymous5280685 / Anonymous5290685. ·Für die Konsensusgruppe Reizdarmsyndrom; Konsensuskonferenz 18./ 19.9.2009. layer@ik-h.de ·Z Gastroenterol · Pubmed #21287438.

ABSTRACT: -- No abstract --

17 Guideline Asian consensus on irritable bowel syndrome. 2010

Gwee, Kok-Ann / Bak, Young-Tae / Ghoshal, Uday Chand / Gonlachanvit, Sutep / Lee, Oh Young / Fock, Kwong Ming / Chua, Andrew Seng Boon / Lu, Ching-Liang / Goh, Khean-Lee / Kositchaiwat, Chomsri / Makharia, Govind / Park, Hyo-Jin / Chang, Full-Young / Fukudo, Shin / Choi, Myung-Gyu / Bhatia, Shobna / Ke, Meiyun / Hou, Xiaohua / Hongo, Michio / Anonymous5550664. ·Stomach Liver and Bowel Clinic, Gleneagles Hospital, Singapore. slbclinic@gmail.com ·J Gastroenterol Hepatol · Pubmed #20594245.

ABSTRACT: BACKGROUND AND AIMS: Many of the ideas on irritable bowel syndrome (IBS) are derived from studies conducted in Western societies. Their relevance to Asian societies has not been critically examined. Our objectives were to bring to attention important data from Asian studies, articulate the experience and views of our Asian experts, and provide a relevant guide on this poorly understood condition for doctors and scientists working in Asia. METHODS: A multinational group of physicians from Asia with special interest in IBS raised statements on IBS pertaining to symptoms, diagnosis, epidemiology, infection, pathophysiology, motility, management, and diet. A modified Delphi approach was employed to present and grade the quality of evidence, and determine the level of agreement. RESULTS: We observed that bloating and symptoms associated with meals were prominent complaints among our IBS patients. In the majority of our countries, we did not observe a female predominance. In some Asian populations, the intestinal transit times in healthy and IBS patients appear to be faster than those reported in the West. High consultation rates were observed, particularly in the more affluent countries. There was only weak evidence to support the perception that psychological distress determines health-care seeking. Dietary factors, in particular, chili consumption and the high prevalence of lactose malabsorption, were perceived to be aggravating factors, but the evidence was weak. CONCLUSIONS: This detailed compilation of studies from different parts of Asia, draws attention to Asian patients' experiences of IBS.

18 Editorial Painful and Painless Constipation: All Roads Lead to (A Change in) Rome. 2018

Bharucha, Adil E / Sharma, Mayank. ·Division of Gastroenterology and Hepatology, College of Medicine, Mayo Clinic, Clinical and Enteric Neuroscience Translational and Epidemiological Research Program (C.E.N.T.E.R.), 200 First St. S.W, Rochester, MN, 55905, USA. bharucha.adil@mayo.edu. · Division of Gastroenterology and Hepatology, College of Medicine, Mayo Clinic, Clinical and Enteric Neuroscience Translational and Epidemiological Research Program (C.E.N.T.E.R.), 200 First St. S.W, Rochester, MN, 55905, USA. ·Dig Dis Sci · Pubmed #29564675.

ABSTRACT: -- No abstract --

19 Editorial Small Intestinal Bacterial Overgrowth and Coronary Artery Disease: What Is in the CArDs? 2018

Adkins, Christopher / Rezaie, Ali. ·GI Motility Program, Division of Gastroenterology, Department of Medicine, Cedars-Sinai, 8730 Alden Drive, Thalians Bldg, #E226, Los Angeles, CA, 90048, USA. · GI Motility Program, Division of Gastroenterology, Department of Medicine, Cedars-Sinai, 8730 Alden Drive, Thalians Bldg, #E226, Los Angeles, CA, 90048, USA. ali.rezaie@cshs.org. ·Dig Dis Sci · Pubmed #29307000.

ABSTRACT: -- No abstract --

20 Editorial Editorial: subgroups in irritable bowel syndrome-more than just diarrhoea and constipation? 2017

Black, C J / Ford, A C. ·Leeds Gastroenterology Institute, St. James's University Hospital, Leeds, UK. · Leeds Institute of Biomedical and Clinical Sciences, University of Leeds, Leeds, UK. ·Aliment Pharmacol Ther · Pubmed #28880445.

ABSTRACT: -- No abstract --

21 Editorial Editorial: subgroups in irritable bowel syndrome-more than just diarrhoea and constipation? Authors' reply. 2017

Polster, A / Van Oudenhove, L / Jones, M / Öhman, L / Törnblom, H / Simrén, M. ·Department of Internal Medicine and Clinical Nutrition, Sahlgrenska Academy, Gothenburg, Sweden. · Translational Research Center for Gastrointestinal Disorders (TARGID), Leuven, Belgium. · Psychology Department, Macquarie University, North Ryde, NSW, Australia. · Department of Microbiology and Immunology, Sahlgrenska Academy, Gothenburg, Sweden. · Center for Functional Gastrointestinal and Motility Disorders, Chapel Hill, NC, USA. ·Aliment Pharmacol Ther · Pubmed #28880440.

ABSTRACT: -- No abstract --

22 Editorial Easing Concerns About the Low FODMAP Diet in Patients With Irritable Bowel Syndrome. 2017

Gibson, Peter R / Burgell, Rebecca E. ·Department of Gastroenterology, Monash University and Alfred Hospital, Melbourne, Victoria, Australia. Electronic address: peter.gibson@monash.edu. · Department of Gastroenterology, Monash University and Alfred Hospital, Melbourne, Victoria, Australia. ·Gastroenterology · Pubmed #28867269.

ABSTRACT: -- No abstract --

23 Editorial Editorial: depression in the setting of inflammatory bowel disease means we have failed to provide early, effective, psychosocial care-authors' reply. 2017

Alexakis, C / Kumar, S / Saxena, S / Hotopf, M / Pollok, R. ·Department of Gastroenterology, St George's University NHS Hospitals Trust, London, UK. · Department of Primary Care and Public Health, Imperial College London, London, UK. · Department of Psychological Medicine, King's College Hospital, London, UK. ·Aliment Pharmacol Ther · Pubmed #28776734.

ABSTRACT: -- No abstract --

24 Editorial Editorial: migration studies to determine risk and cause of inflammatory bowel disease-authors' reply. 2017

Damas, Oriana M / Schwartz, Seth J / Abreu, Maria T. ·Division of Gastroenterology, Department of Medicine, University of Miami Miller School of Medicine, Miami, FL, USA. · Department of Public Health Sciences, University of Miami Miller School of Medicine, Miami, FL, USA. ·Aliment Pharmacol Ther · Pubmed #28707792.

ABSTRACT: -- No abstract --

25 Editorial Rifaximin Re-treatment in Patients with Irritable Bowel Syndrome: Feels Like the First Time? 2017

Ponziani, Francesca Romana / Pompili, Maurizio / Gasbarrini, Antonio. ·Internal Medicine, Gastroenterology and Hepatology, Agostino Gemelli Hospital, Largo A. Gemelli 8, 00168, Rome, Italy. francesca.ponziani@yahoo.it. · Internal Medicine, Gastroenterology and Hepatology, Agostino Gemelli Hospital, Largo A. Gemelli 8, 00168, Rome, Italy. ·Dig Dis Sci · Pubmed #28646286.

ABSTRACT: -- No abstract --

Next